Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Habauzit

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Comparative Effectiveness Research|October 19, 2023
Navigating adalimumab biosimilars: an expert opinionVered Abitbol, Salim Benkhalifa, Caroline Habauzit, et al.
Rheumatology and Therapy|February 28, 2025
The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with RecommendationsJérôme Avouac, Hafid Ait-Oufella, Caroline Habauzit, et al.
Crohn'S & Colitis 360|March 6, 2026
Subcutaneous infliximab in inflammatory bowel disease: bridging the gap between theory and practiceLucine Vuitton, Mathurin Fumery, Lucile Foulley, et al.
Rheumatology and Therapy|March 16, 2026
Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER StudyLaure Gossec, Guillaume Bouguen, Azeddine Dellal, et al.
Expert Opinion on Biological Therapy|May 27, 2026
Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectivesLaure Gossec, Hubert Marotte, Ziad Reguiai, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 25, 2024
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER StudyGuillaume Bouguen, Laure Gossec, Vered Abitbol, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Comparative Effectiveness Research|October 19, 2023
Navigating adalimumab biosimilars: an expert opinionVered Abitbol, Salim Benkhalifa, Caroline Habauzit, et al.
Rheumatology and Therapy|February 28, 2025
The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with RecommendationsJérôme Avouac, Hafid Ait-Oufella, Caroline Habauzit, et al.
Crohn'S & Colitis 360|March 6, 2026
Subcutaneous infliximab in inflammatory bowel disease: bridging the gap between theory and practiceLucine Vuitton, Mathurin Fumery, Lucile Foulley, et al.
Rheumatology and Therapy|March 16, 2026
Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER StudyLaure Gossec, Guillaume Bouguen, Azeddine Dellal, et al.
Expert Opinion on Biological Therapy|May 27, 2026
Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectivesLaure Gossec, Hubert Marotte, Ziad Reguiai, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 25, 2024
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER StudyGuillaume Bouguen, Laure Gossec, Vered Abitbol, et al.
Pageof 1